Liendax (Liraglutide)

Liraglutide mimics the natural hormone GLP‑1 by binding to the GLP‑1 receptor on pancreatic beta cells. This activation enhances glucose‑dependent insulin secretion, suppresses glucagon release, and slows gastric emptying, together lowering post‑prandial glucose levels and improving overall glycaemic control.

The dose of Liendax is individualized. A qualified prescriber determines the starting dose and any titration steps based on the patient’s glycaemic targets, renal function, tolerability, and other clinical factors, following the approved labeling.

Safety data for liraglutide during pregnancy and lactation are limited. It should only be used if the potential benefit to the mother justifies any potential risk to the fetus or infant, and the decision must be made by the treating physician.

To place an order, submit an enquiry on the Liendax product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and necessary import documentation.

Liendax (liraglutide) shares the class‑wide GLP‑1 receptor activation mechanism but differs in dosing frequency (once‑daily) and specific efficacy and safety profiles compared with weekly agents such as dulaglutide or semaglutide. Choice of agent depends on patient preference, clinical response, and tolerability.

Liendax should be stored at 2 °C to 8 °C (refrigerated) in its original carton, protected from light. Do not freeze or shake the vial. If temporary storage at room temperature is required, keep it away from direct heat for no more than 30 days.

Liendax is supplied as a sterile solution for subcutaneous injection. It is administered once daily using a pre‑filled pen or syringe, injected into the abdomen, thigh or upper arm, rotating sites with each dose to minimise local irritation.

The most serious safety concerns with liraglutide include pancreatitis, severe hypoglycaemia (especially when combined with insulin or sulfonylureas), gallbladder disease, acute kidney injury, and, although rare, thyroid C‑cell tumours observed in rodent studies. Patients should promptly report persistent abdominal pain, signs of low blood sugar, or unexplained jaundice.

Liendax is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, and in patients with known hypersensitivity to liraglutide or any excipients. Caution is also advised in severe renal impairment.